Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...

RFK Jr. plans to keep collecting referral fees in lawsuits against the drug company Merck even if confirmed as HHS secretary, ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Belén Garijo, CEO of Merck KGaA, weighs in on Europe's competitiveness and the pharma giant's preparations for the impact of ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

(Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $113 from $123 and keeps an Equal Weight rating on the ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other large-cap value stocks. Why is this Portfolio Manager Cautiously Optimistic? The market ...